Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market
- 2026 年市場規模
- USD 1,926.8 Mn
- 2033 年預估規模
- USD 3,207.6 Mn
- 年複合成長率 CAGR
- 7.7%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Drug Class (Pleuromutilin Antibiotic, Cephalosporin, Glycylcycline, Oxazolidinone, Ketolide, Others), By Dose Form (Solution, Tablet), By Route of Administration (Oral, Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
報告摘要
Community-acquired bacterial pneumonia (CABP) is most common acute respiratory illnesses among various infections triggering sepsis. Microbiologically, bacteria are common agents causing pneumonia, with Streptococcus pneumoniae being the most common cause worldwide. CABP is the most common infectious causes of illness and hospitalization, especially in the geriatric population. For instance, according to the National Center for Biotechnology Information (NCBI), in March 2020, the incidence of community-acquired pneumonia (CAP) in the U.S. is more than 5 million per year.
Market Dynamics
Inorganic strategies amongst key players are strengthening the companies’ market share in global community-acquired bacterial pneumonia (CABP) treatment drugs market. For instance, in 2017, Avir Pharma Inc. (Avir), an affiliate of the Laboratoire RIVA Group, entered into a Canadian distribution and license agreement with Basilea Pharmaceutica Ltd. for its antifungal Cresemba (isavuconazole) and antibiotic Zevtera (ceftobiprole). Avir plans to apply for a marketing authorization for isavuconazole in Canada. Zevtera is already approved by Health Canada for the treatment of adult patients with hospital-acquired pneumonia (HAP) and for the treatment of community-acquired pneumonia (CAP) and will be purchasing product from Basilea and will commercialize in Canada.
However, antibiotic resistance in drugs is hampering the market growth. For instance, according to an article published in November 2019 in the National Center for Biotechnology Information (NCBI), in pneumococcal pneumonia, beta-lactam as monotherapy may not be optimal therapy even if bacteria remain susceptible to the beta-lactam. Therefore, antibiotic resistance are expected to restrain the global community-acquired bacterial pneumonia (CABP) treatment drugs market.
Key features of the study
• This report provides in-depth analysis of the global community-acquired bacterial pneumonia (CABP) treatment drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global community-acquired bacterial pneumonia (CABP) treatment drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study are Nabriva Therapeutics, Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Bayer AG, Lupin Pharmaceuticals, Inc., Mylan N.V., Sanofi S.A., Pfizer Inc., Dainippon Sumitomo Pharma, Takeda Pharmaceutical Company Limited, and Basilea Pharmaceutica International AG.
• Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
• The global community-acquired bacterial pneumonia (CABP) treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global community-acquired bacterial pneumonia (CABP) treatment drugs market.
Market Segmentation
• By Drug Class (Revenue, USD Mn, 2021-2033)
o Pleuromutilin Antibiotic
o Cephalosporin
o Glycylcycline
o Oxazolidinone
o Ketolide
o Others
• By Dose Form (Revenue, USD Mn, 2021-2033)
o Solution
o Tablet
• By Route of Administration (Revenue, USD Mn, 2021-2033)
o Oral
o Intravenous
• By Distribution Channel (Revenue, USD Mn, 2021-2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Region: (Revenue, USD Mn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Company Profiles
o Nabriva Therapeutics
o Paratek Pharmaceuticals, Inc.
o Melinta Therapeutics, Inc.
o Allergan plc
o Bayer AG
o Lupin Pharmaceuticals, Inc.
o Mylan N.V.
o Sanofi S.A.
o Pfizer Inc.
o Dainippon Sumitomo Pharma
o Takeda Pharmaceutical Company Limited
o Basilea Pharmaceutica International AG
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snippet, By Drug Class
Market Snippet, By Dose Form
Market Snippet, By Route of Administration
Market Snippet, By Distribution Channel
Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Pipeline Analysis
o Reimbursement Scenario
o Epidemiology
o Pest Analysis
o Regulatory Scenario
o New Product Launches
o Collaborations and Agreements
o Market Trends
4. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Drug Class, 2021 – 2033, (US$ Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Pleuromutilin Antibiotic
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
o Cephalosporin
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
o Glycylcycline
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
o Oxazolidinone
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
o Ketolide
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
5. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Dose Form, 2021 – 2033, (US$ Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Solution
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
o Tablet
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
6. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Route of Administration, 2021 – 2033, (US$ Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
o Intravenous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
7. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Distribution Channel, 2021 – 2033, (US$ Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021 – 2033, (US$ Mn)
8. Global Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market, By Region, 2021 – 2033, (US$ Mn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022 – 2033
o North America
Market Size and Forecast, By Drug Class, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Dose Form, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Country, 2021 – 2033, (US$ Mn)
o U.S.
o Canada
o Latin America
Market Size and Forecast, By Drug Class, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Dose Form, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Country, 2021 – 2033, (US$ Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Market Size and Forecast, By Drug Class, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Dose Form, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Country, 2021 – 2033, (US$ Mn)
o Germany
o U.K.
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Market Size and Forecast, By Drug Class, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Dose Form, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Country, 2021 – 2033, (US$ Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Market Size and Forecast, By Drug Class, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Dose Form, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Country, 2021 – 2033, (US$ Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
Market Size and Forecast, By Drug Class, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Dose Form, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Route of Administration, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2021 – 2033, (US$ Mn)
Market Size and Forecast, By Country/Region, 2021 – 2033, (US$ Mn)
o South Africa
o Central Africa
o North Africa
9. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
Nabriva Therapeutics
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Paratek Pharmaceuticals, Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Melinta Therapeutics, Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Allergan plc
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Bayer AG
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Lupin Pharmaceuticals, Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Mylan N.V.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Sanofi S.A.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Pfizer Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Dainippon Sumitomo Pharma
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Takeda Pharmaceutical Company Limited
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Basilea Pharmaceutica International AG
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
o Analyst Views
10. Section
o References
o Research Methodology
o About us and Sales Contact
*Browse 42 market data tables and 26 figures on Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market” - Global forecast to 2033
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們